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Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increas-
ing global threat. Here, we describe the prevalence and impact of
tigecycline use in a cohort of patients with CRKP bacteriuria
nested within a multicentre, prospective study. In the 21-month
study period, 260 unique patients were included. Tigecycline was
given to 80 (31%) patients. The use of tigecycline during the index
hospitalization was significantly associated with the subsequent
development of tigecycline resistance in the same patient (OR,
6.13; 95% CI, 1.15–48.65; p 0.03). In conclusion, the use of
tigecycline with CRKP bacteriuria is common, and is associated
with the subsequent development of tigecycline resistance.
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Resistance to carbapenems in Enterobacteriaceae (CRE) is
increasing globally [1]. Among CRE, carbapenem-resistant
Klebsiella pneumoniae (CRKP) is most prevalent. CRKP are
generally resistant to multiple antibiotic classes. As a result,
treatment options for CRKP include polymyxins, tigecycline,
aminoglycosides and fosfomycin, which are limited by concerns
regarding efficacy and safety [2]. In addition, resistance to colistin
and tigecycline is increasingly reported [3–5]. The molecular
epidemiology of CRKP is currently being evaluated by the
Carbapenem Resistance Consortium for Klebsiella pneumoniae
(CRaCKle) [6]. This multicentre consortium is comprised of five
health systems, which include community-based hospitals and
tertiary care referral centres ranging in size from 25 beds and
over 700 annual admissions to over 1400 beds and over 50 000
annual admissions. None of the hospitals performed screening
for asymptomatic CRKP carriage during the study period. Here,
we analyze tigecycline use in the cohort of patients with CRKP
bacteriuria nested within CRaCKle.
CRKP are defined as K. pneumoniae isolates with decreased
susceptibility to any of the carbapenems (MIC ≥ 2 mg/L).
Bacterial identification and routine antimicrobial susceptibility
testing was performed with MicroScan (Siemens Healthcare
Diagnostics, Malvern, PA, USA) or Vitek2 (BioMerieux,
Durham, NC, USA), supplemented by the GN4F Sensititre
tray (Thermo Fisher, Waltham, MA, USA) to confirm carba-
penem results and to test tigecycline susceptibility. For
tigecycline, European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) breakpoints were used (susceptible
MIC <2 mg/L, intermediate MIC = 2 mg/L and resistant MIC
>2 mg/L). The Institutional Review Boards of all health systems
involved approved the study.
Within the study period of 24 December 2011 until 1
October 2013, 260 unique patients with CRKP bacteriuria
were included (Table 1); 73 patients met criteria for urinary
tract infection (UTI), which was defined as outlined by the
Centers for Disease Control/National Healthcare Safety
Network (CDC/NHSN) [7]. In addition, patients were
deemed to have infection if they had a CRKP bloodstream
infection within 48 h of the positive urine culture even if CDC/
NHSN criteria were not met.
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Eighty (31%) patients received tigecycline during their index
hospitalization. Each patient was only included once at the time
of their first urine culture from which CRKP was isolated.
Severe acute illness (defined as a Pitt bacteraemia score
greater than or equal to four points, on the day of the index
urine culture [8]) was more common in patients treated with
tigecycline. At the time of culture, most patients had
non-physiological urinary drainage, defined as indwelling
urinary catheter, intermittent catheterization or permanent
urinary diversion (65%). A difference in distribution of the
method of urinary drainage was observed for patients treated
with tigecycline; in the tigecycline group 24% had physiological
drainage, as compared with 41% of others (p 0.04). During the
index hospitalization, 36 (14%) patients had CRKP isolated
from other anatomical sites in addition to the urine. Tigecy-
cline treatment was associated with CRKP isolated from other
TABLE 1. Demographics, comorbidities and outcomes
All Tigecycline No tigecycline
pn 260 80 180
Baseline characteristics
Age, median (IQR) 71 (61–81) 72 (62–79) 71 (60–83) 0.80f
Gender, female 162 (62) 47 (58) 115 (64) 0.49
Race
White, non-Hispanic 141 (54) 42 (53) 99 (55) 0.54
Black, non-Hispanic 106 (41) 34 (43) 72 (40)
Hispanic 6 (2) 3 (2) 3 (2)
Other 7 (3) 1 (1) 6 (3)
Diabetes mellitus 141 (54) 43 (54) 98 (54) 1.00
Heart diseasea 139 (53) 40 (50) 99 (55) 0.50
Renal failure 67 (26) 16 (20) 51 (28) 0.17
COPD 72 (28) 20 (25) 52 (29) 0.55
Malignancy 38 (15) 11 (14) 27 (15) 0.85
Dementia 56 (22) 17 (21) 39 (22) 1.00
Immunocompromiseb 19 (7) 5 (6) 14 (8) 0.80
Charlson, median (IQR) 3 (2–5) 3 (2–6) 3 (2–5) 0.82
Origin
Skilled nursing facility 132 (51) 46 (58) 86 (48) 0.50g
Home 80 (31) 20 (25) 60 (33)
Hospital transfer 32 (12) 9 (11) 23 (12)
Long-term acute care 16 (6) 5 (6) 11 (6)
Infection 73 (28) 27 (34) 46 (26) 0.18
Location at time of culture
Emergency department 90 (35) 27 (34) 63 (35) 0.27
Ward 117 (45) 32 (40) 85 (47)
Intensive care unit 53 (20) 21 (26) 32 (18)
Pitt bacteraemia score ≥ 4 60 (23) 26 (33) 34 (19) 0.025
Days to first positive culture, median (IQR) 0 (0–3) 0 (0–2) 0 (0–3) 0.93
Urinary drainage
Physiological 92 (35) 19 (24) 73 (41) 0.04g
Foley catheter 129 (50) 50 (63) 79 (44)
Intermittent catheterization 18 (7) 5 (6) 13 (7)
Permanent urinary diversionc 21 (8) 6 (8) 15 (8)
Urine wbc
Not performed 71 (27) 22 (28) 49 (27) 0.12h
0–5 cells/hpf 13 (5) 4 (5) 9 (5)
5–10 cells/hpf 13 (5) 3 (4) 10 (6)
10–25 cells/hpf 33 (13) 6 (8) 27 (15)
>25 cells/hpf 130 (50) 45 (56) 85 (47)
Outcomes
CRKP at other sitesd
None 224 (86) 60 (75) 164 (91) 0.0009
Blood 14 (5) 7 (9) 7 (4) 0.14
Respiratory 9 (3) 4 (5) 5 (3) 0.46
Wound 12 (5) 9 (11) 3 (2) 0.002
Other 2 (1) 0 (0) 2 (1) 1.00
Length of stay, days, median (IQR) 9 (5–15) 12 (7–18) 8 (5–14) 0.001f
ICU admission 119 (46) 46 (57) 73 (41) 0.015
Days in ICU, median (IQR)e 6 (3–13) 10 (5–16) 3 (4–9)
Disposition after hospitalization
Death/hospice 29 (11) 13 (16) 16 (9) 0.23i
Home 59 (23) 11 (14) 48 (27)
Skilled nursing facility 127 (49) 34 (43) 93 (52)
Long-term acute care 41 (16) 21 (26) 20 (11)
Transfer to other hospital 4 (2) 1 (1) 3 (2)
All data are listed as n (%), unless otherwise indicated.
aCoronary artery disease and/or heart failure.
b10 mg/day prednisone or equivalent corticosteroid dosing, solid organ or stem cell transplant recipient.
cIncludes suprapubic catheter and ileal conduit.
dDuring index admission (totals do not add to 100%, as some patients had CRKP isolated from more than one additional anatomical site). CRKP, carbapenem-resistant
K. pneumoniae.
eIn those patients with an ICU admission.
fMedian test.
gPearson.
hOrdinal logistic for those with urinalysis performed.
iMultivariate nominal logistic model adjusted for infection, Pitt score, drainage and additional CRKP source.
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sites; 25% of patients treated with tigecycline had CRKP at
other sites, as compared with 9% of those who did not receive
tigecycline (p 0.0009).
Tigecycline treatment was not associated with a change in
the rate of readmissions during which CRKP was again isolated
in culture (Fig. 1). Tigecycline susceptibility data were available
for the index culture and subsequent CRKP isolates in 36
patients with readmissions (Fig. 1). Five of the index isolates
were resistant to tigecycline. In the remaining 31 patients,
increasing resistance was noted in 11/31 (35%) patients; six
patients had a susceptible index isolate and a resistant isolate
upon readmission, one isolate went from intermediate to
resistant, and four isolates went from susceptible to interme-
diate. The use of tigecycline was independently associated with
the development of subsequent tigecycline resistance (OR,
6.13; 95% CI, 1.15–48.65; p 0.03). Tigecycline resistance
developed in 4/18 (22%) patients who did not receive
tigecycline, as compared with 7/13 (54%) patients who were
treated with tigecycline. In these seven patients, the median
time from index culture to first isolation of a more resistant
isolate was 65 days (IQR, 31–77 days).
A non-significant trend was seen towards more develop-
ment of tigecycline resistance in patients with spontaneous
physiological urinary drainage (OR, 4.56; 95% CI, 0.83–36.24;
p 0.08), as compared with patients with indwelling bladder
catheters and other methods of non-physiological urinary
drainage, such as intermittent straight catheterization. Both
the susceptible and the non-susceptible strains were available
for strain typing in three of 11 patients in whom tigecycline
resistance developed. Repetitive extragenic palindromic
(rep)-PCR was used (DiversiLab Strain typing system, Bacterial
BarCodes, bioMerieux, Athens, GA, USA), with ≥95% similar-
ity considered as the same rep-PCR type [9]. In all three
patients the strains were identical.
In this cohort, we noted frequent use of tigecycline, as well as
a concerning baseline rate of tigecycline resistance. The
association between tigecycline use and subsequent tigecycline
resistance was previously evaluated in a case-control study in
K. pneumoniae isolates that produced either extended spectrum
beta lactamases (ESBL) and/or K. pneumoniae carbapenemases
(KPC); a similar magnitude of effect between tigecycline use and
tigecycline resistance (OR, 6.00) was reported [10]. The current
study provides concordant evidence; important strengths of the
current study are that we show the longitudinal and directional
development of tigecycline resistance with prospectively col-
lected data, and the molecular analysis confirming that initial
susceptible strains and subsequent resistant strains in a given
patient were identical.
Limitations include the potential for confounding by indica-
tion, and the lack of an objective method to distinguish
asymptomatic bacteriuria from UTI. We chose to include all
patients with CRKP bacteriuria, as treatment is common in
260 patients with CRKP bacteriuria
–73 with CRKP UTI
13 death/hospice
44 no CRKP readmission
1 index isolate resistant 
to tigecycline
9 missing tigecycline 
susceptibility data
13 evaluable patients at risk for 
increasing tigecycline resistance
7 patients with 
increasing tigecycline resistance
6 patients without
increasing tigecycline resistance
23 CRKP readmission 44 CRKP readmission
180 did not receive tigecycline
–46 with CRKP UTI
80 received tigecycline
–27 with CRKP UTI
18 evaluable patients at risk for 
increasing tigecycline resistance
4 patients with 
increasing tigecycline resistance
14 patients without
increasing tigecycline resistance
16 death/hospice
120 no CRKP readmission
4 index isolates resistant 
to tigecycline
22 missing tigecycline 
susceptibility data
FIG. 1. Diagram outlining patient flow
throughout the study. CRKP, carba-
penem-resistant Klebsiella pneumoniae.
UTI, urinary tract infection. CRKP
readmission is defined as any readmission
during which CRKP was again isolated
from a clinical culture from any anatomical
site.
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those patients who do not meet the CDC/NHSN criteria for
UTI, which were primarily designed for surveillance purposes.
Lastly, of the total 260 patients included in this study, only 31
could be included in the analysis of the influence of tigecycline
use on subsequent tigecycline resistance. Independent confir-
mation from other cohorts will be required for ultimate
validation of our findings.
In summary, the use of tigecycline in patients with CRKP
bacteriuria, while infrequently indicated, was relatively com-
mon in this population. We have shown that the use of
tigecycline in patients with CRKP bacteruria is associated with
rapid development of in vitro resistance.
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